Werewolf Therapeutics
61 articles about Werewolf Therapeutics
-
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
4/5/2024
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) is presenting preclinical data on development candidates WTX-518 and WTX-712 in posters at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.
-
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
4/4/2024
Werewolf Therapeutics, Inc. announced the publication of an abstract for an upcoming poster presentation at IMMUNOLOGYTM 2024, the annual meeting of the American Association of Immunologists taking place May 3-7 in Chicago, Illinois.
-
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
3/7/2024
Werewolf Therapeutics, Inc. today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.
-
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
3/6/2024
Werewolf Therapeutics, Inc. today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 9:20 AM ET on March 13, 2024, at the Leerink Partners Global Biopharma Conference, taking place March 11-13, 2024, in Miami, Florida.
-
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
3/5/2024
Werewolf Therapeutics, Inc. announced the publication of abstracts for upcoming poster presentations at the American Association for Cancer Research Annual Meeting 2024, taking place April 5-10 in San Diego, California.
-
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
1/8/2024
Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, provided a business update and outlined its strategic outlook and expected milestones for 2024.
-
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
1/4/2024
Werewolf Therapeutics, Inc. announced the appointment of Michael B. Atkins, M.D., to its Board of Directors.
-
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
11/22/2023
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 8:20 AM ET on November 29 at the Evercore ISI HealthCONx Conference, taking place November 28-30, 2023, in Miami, Florida.
-
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
11/14/2023
Werewolf Therapeutics, Inc. provided a business update and reported financial results for the third quarter ended September 30, 2023.
-
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
11/3/2023
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced preliminary first-in-human clinical data from initial monotherapy dose-escalation cohorts in the Company’s lead clinical program, WTX-124x2101.
-
Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
10/31/2023
Werewolf Therapeutics, Inc. today announced that a poster describing interim first-in-human clinical results from initial monotherapy dose-escalation cohorts in the ongoing Phase 1/1b study of WTX-124 will be presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, taking place November 1-5, 2023 in San Diego, California.
-
Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
9/27/2023
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced the publication of abstracts for upcoming poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, taking place November 1-5, 2023 in San Diego, California.
-
Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124Virtual event to be held on Monday, September 18, 2023, at 10:00 am ET
9/11/2023
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that it will host a virtual R&D Event on Monday, September 18, 2023, at 10:00 am ET.
-
Werewolf Therapeutics to Participate in Upcoming September 2023 Investor Conferences
9/5/2023
Werewolf Therapeutics, Inc. announced that management will participate in the following upcoming investor conferences in the month of September:
-
Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
8/10/2023
Werewolf Therapeutics, Inc. today provided a business update and reported financial results for the second quarter ended June 30, 2023.
-
Werewolf Therapeutics to Present at the 2023 Jefferies Healthcare Conference
6/1/2023
Werewolf Therapeutics, Inc. announced that management will present a company overview at 4:00 PM ET on June 8 at the Jefferies Healthcare Conference, taking place June 7th-9th, 2023, in New York, NY.
-
Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
5/11/2023
Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, provided a business update and reported financial results for the first quarter ended March 31, 2023.
-
Werewolf Therapeutics to Participate in May Investor Conferences
5/1/2023
Werewolf Therapeutics, Inc. today announced that management will participate at the following conferences in the month of May.
-
Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research
4/19/2023
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics, announced the publication in Cancer Immunology ResearchOnline First of preclinical data for mWTX-330, a systemically delivered Interleukin-12 (IL-12) INDUKINETM molecule.
-
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3/23/2023
Werewolf Therapeutics, Inc. today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022.